ArticleNature cancer2025
IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR
Erratum issuedAbstract read
In one paragraph
Article in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CDK4/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates.Frontiers in immunology · 2026Pooled it
- The peripheral immune landscape of human breast cancer.Oncoimmunology · 2026Review
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- Targeting the tumor microenvironment: a new strategy for natural products in breast cancer therapy.Natural products and bioprospecting · 2026Review
- Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Metabolism, autophagy, and cell death: The triangular axis in tumor survival and therapeutic resistance.Redox biology · 2026Review
- γδ T cells and cancer.The Journal of clinical investigation · 2026Review
- Autophagy modulation in cancer.Nature reviews. Drug discovery · 2026Review
- Silencing SLC52A2 promotes tertiary lymphoid structure formation and inhibits IL-17 pathway to ameliorate melanoma progression.Apoptosis : an international journal on programmed cell death · 2026Article
- Immune surveillance and immune evasion of senescent cells.Nature reviews. Immunology · 2026Review
- Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance.ACS pharmacology & translational science · 2026Review
- Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer.Immuno-oncology technology · 2026Article
- Effector Vδ1 γδ T cells mediate anti-tumor immunity and are reprogrammed by imatinib in human gastrointestinal stromal tumor.Research square · 2026Article
- Germline BRCA2 mutations foster resistance to CDK4/6 inhibitors in breast cancer.NPJ precision oncology · 2026Article
- NKG2A inhibition promotes NK cell-CD8Nature communications · 2026Article
- Exploring the mechanism of action of abemaciclib in breast cancer through circulating chromatin fragments.Communications medicine · 2026Article
- Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression.Molecular cancer · 2026Review
- Molecular innate immune programs of tumor-associated macrophages in immune checkpoint blockade resistance: a staged framework from suppressive circuitry to translational bottlenecks.Frontiers in immunology · 2026Review
- Translational potential of γδ T cells in hematologic diseases: from immunobiology to therapeutic innovation.Frontiers in immunology · 2026Review
- Cyclin-dependent kinase 4 and 6 inhibitors and the breast cancer immune ecosystem: immune remodeling, resistance, and therapeutic reprogramming.Frontiers in immunology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
37 authors.
Giulia Petroni *Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0002-0558-5322
Claudia Galassi *Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Kenneth H Gouin *Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Hsiang-Han ChenDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-1329-3298
Aitziber BuquéDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0002-7698-8778
Norma BloyDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Takahiro YamazakiDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0002-7420-4394
Ai SatoDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0002-5408-2596
Manuel Beltrán-VisiedoDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0002-7977-8020
Ginevra CampiaDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Carlos Jiménez-CorteganaDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Aagam ShahDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Alexander KirchmairBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0003-2284-7424
Chiara MassaInstitute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Claudia WickenhauserInstitute of Pathology, University Hospital Halle, Halle, Germany.
Carlos Eduardo de AndreaDepartment of Anatomy, Physiology and Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
Belén Navarro-RubioDepartment of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Irantzu Serrano-MendiorozDepartment of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.
Esther Navarro ManzanoCentro Regional de Hemodonación, Murcia, Spain.
Alexandra M SattyDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Brady RipponDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Francesca FinotelloBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0003-0712-4658
Zlatko TrajanoskiBiocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0002-0636-7351
Xi Kathy ZhouDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-8942-439X
Joseph M ScanduraDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-9525-143X
Elena García-MartínezInstituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain.
Francisco Ayala de la PeñaInstituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain.ORCID http://orcid.org/0000-0001-6311-920X
María Esperanza Rodríguez-RuizDepartment of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Barbara SeligerInstitute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Víctor Sánchez-MargaletDepartment of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, Universidad de Sevilla, Sevilla, Spain.
Luis de la Cruz-MerinoDepartment of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, Universidad de Sevilla, Sevilla, Spain.
Reva K BashoEllison Institute of Technology, Los Angeles, CA, USA.
Stephen L ShiaoDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Heather L McArthurInternal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Silvia C FormentiDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. deadoc80@gmail.com.
Simon R V KnottDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. formenti@med.cornell.edu.ORCID http://orcid.org/0000-0002-4018-7653
Lorenzo GalluzziDepartment of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. simon.knott@cshs.org.ORCID http://orcid.org/0000-0003-2257-8500
Funding
EIF | Stand Up To Cancer (SU2C) #ZP-6177U.S. Department of Defense (United States Department of Defense) #BC210945
Abstract
Resistance to cyclin-dependent kinase 4/6 (CDK4/CDK6) inhibitors leads to treatment failure and disease progression in women with hormone receptor
Indexed as
Breast NeoplasmsCX3C Chemokine Receptor 1Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Drug Resistance, NeoplasmInterleukin-17Intraepithelial LymphocytesProtein Kinase InhibitorsTumor-Associated MacrophagesAnimalsErb-b2 Receptor Tyrosine KinasesFemaleHumansMacrophagesMiceReceptors, EstrogenCDK4 protein, humanCDK6 protein, humanCX3C Chemokine Receptor 1CX3CR1 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesIL17A protein, humanInterleukin-17Protein Kinase InhibitorsReceptors, Estrogen
Identifiers
PMID
40624238What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.